Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.51 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | BCR | P11274 | 2/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.46 |
| ▸ | GSK3A | P49840 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12899166 | 0.93 | GSK3B (0.56) | GSK3BAAK1GSK3APIK3CDPIM1 | |
| SCHEMBL4480802 | 0.92 | CHRM3 (0.47) | GSK3BAAK1GSK3AHDAC6 | |
| SCHEMBL12886233 | 0.91 | GSK3B (0.45) | GSK3BACKR3AAK1GSK3APIK3CD | |
| SCHEMBL4488374 | 0.91 | HDAC6 (0.53) | GSK3BAAK1GSK3APIK3CDPIM1 | |
| SCHEMBL12899596 | 0.90 | LCK (0.45) | GSK3BAAK1GSK3APIK3CDPIM1 | |
| SCHEMBL12886077 | 0.90 | HDAC6 (0.51) | GSK3BAAK1GSK3APIK3CDPIM1 | |
| SCHEMBL12899164 | 0.89 | GSK3B (0.47) | GSK3BAAK1GSK3APIK3CDPIM1 | |
| SCHEMBL4500034 | 0.88 | GSK3B (0.58) | GSK3BACKR3AAK1GSK3APIK3CD | |
| SCHEMBL4486750 | 0.87 | HDAC1 (0.59) | GSK3BAAK1GSK3AHDAC6 | |
| SCHEMBL4499391 | 0.87 | AAK1 (0.61) | GSK3BAAK1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | claimed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | GSK3B 5/4885ACKR3 1269/4885ABL1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.